tirzepatide+ Hush Medical Spa Compounded Tirzepatide Weight Loss Program

Boehringer Ingelheim is cashing in on its diabetes franchise related to sodium glucose co-transporter-2 (SGLT-2) inhibitor empagliflozin in India ahead of the local patent expiry for the molecule in March 2025

In SURMOUNT-1: Tirzepatide 5 mg: Mean 15.0% body weight loss at 72 weeks Tirzepatide 10 mg: Mean 19.5% body weight loss at 72 weeks Tirzepatide 15 mg: Mean 20.9% body weight loss at 72 weeks Placebo: 3.1% body weight loss at 72 weeks On a per-week basis, most patients lose 12 pounds weekly during titration and the first 6 months, with the rate gradually slowing as the body approaches a new metabolic equilibrium

No nausea on this versus semaglutide I was ill every day

The clinical utility of many microbiome tests remains debated among gastroenterologists and researchers

Nature Reviews Endocrinology, 2020

More options than anyone else